Peer-reviewed veterinary case report
Bedinvetmab works as well as grapiprant for dog arthritis pain
By Enomoto, Masataka et al.·Published in Scientific reports·2026·College of Veterinary Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A noninferiority trial evaluating the efficacy of bedinvetmab compared to grapiprant for osteoarthritis-pain in dogs using force plate gait analysis.
- Species:
- dog
Plain-English summary
A study looked at how well two treatments worked for dogs with osteoarthritis (OA) pain, specifically in their hips and knees. Thirty-two dogs received either bedinvetmab, given as a monthly injection, or grapiprant, taken daily as a pill. After two months, both treatments showed improvement in pain and movement, with bedinvetmab performing slightly better. Both medications were found to be safe and effective options for managing OA pain in dogs.
People also search for: dog osteoarthritis treatment · bedinvetmab for dogs · grapiprant for dog pain · how to help dog with joint pain
Abstract
A randomized, double-blind, non-inferiority study was conducted to evaluate efficacy of bedinvetmab compared to grapiprant using objective force plate gait analysis (FPGA). Thirty-two eligible dogs (> 20 kg, ≥ 1 year-old) with osteoarthritis (OA) exclusively at hips and/or stifles were randomized 1:1 to the licensed dose of monthly subcutaneous (SC) bedinvetmab (plus daily oral placebo) or daily oral grapiprant (plus monthly SC saline) beginning on day 0 (D0). FPGA and client-reported outcome measures (CROMs) were collected at screening, D0, and every 14 days for 2 months. Based on published FPGA parameters, success-failure rates were calculated for each group. A non-inferiority margin of 21.25% at D42 was defined a priori. FPGA treatment success rate at D42 was 68.8% for bedinvetmab and 56.3% for grapiprant, with the difference being 12.5% (90% confidence interval = -37.5, 18.8). Given that the upper bound of this interval (18.8%) was less than the pre-specified non-inferiority margin of 21.25%, bedinvetmab was concluded to be non-inferior to grapiprant. Overall, pain and associated clinical signs were significantly improved after both treatments based on CROMs. Adverse events were in line with respective label expectations. These data support both bedinvetmab and grapiprant are appropriate first-line treatments for OA pain in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41667566/